Cell Therapies
Total Trials
3
As Lead Sponsor
As Collaborator
0
Total Enrollment
125
NCT05580991
Intratumoral CAN1012(selective TLR7 Agonist) in Subjects with Solid Tumors
Phase: Phase 1
Role: Lead Sponsor
Start: Sep 9, 2022
Completion: Jun 30, 2025
NCT06332430
Intratumoral CAN2109 in Subjects With Solid Tumors
Start: May 28, 2024
Completion: May 30, 2026
NCT06410703
CAN1012 Combined With PD-1 in Patients With Solid Tumors
Phase: Phase 1/2
Start: Jun 27, 2024
Loading map...